Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Neoadjuvant Ivonescimab in Patients With High-Risk, Localized RCC

NCT07226544 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07226544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Neoadjuvant Ivonescimab in Patients With High-Risk, Localized RCC
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2026
Completion date
September 8, 2027
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

localized clear cell renal cell carcinoma, resectable clear cell renal cell carcinoma, stage ii renal cell cancer ajcc v8, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8